NEW
YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders
of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Shareholders who purchased shares of NMRA during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=128956&from=4
CLASS PERIOD: This lawsuit is on behalf of a class of all
persons or entities who purchased or otherwise acquired Neumora
common stock pursuant and/or traceable to the Offering Documents,
commenced on or about September 15,
2023.
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (1) in order
for Neumora to justify conducting its Phase Three Program, Neumora
was forced to amend BlackThorn's original Phase Two trial inclusion
criteria to include a patient population with moderate to severe
Major Depressive Disorder, MDD, to show that Navacaprant, Neumora's
flagship therapeutic candidate, offered a statistically significant
improvement in treating MDD; (2) and to that same end, the Company
also added a prespecified analysis to the Phase Two statistical
analysis plan, focusing on patients suffering from moderate to
severe MDD; and (3) the Phase Two Trials lacked adequate data,
particularly in regards to the patient population size and the
ratio of male to female patients within the patient population, to
be able to accurately predict the results of the KOASTAL-1
study.
DEADLINE: April 7, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=128956&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of NMRA during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is April 7, 2025. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-neumora-therapeutics-inc-nmra-seeking-recovery-for-investors--contact-the-gross-law-firm-302375170.html
SOURCE The Gross Law Firm
